Intra-Cellular Therapies (ITCI) Receives FDA Approval of Novel Antipsychotic, CAPLYTA for Treatment of Schizophrenia in Adults
Go back to Intra-Cellular Therapies (ITCI) Receives FDA Approval of Novel Antipsychotic, CAPLYTA for Treatment of Schizophrenia in Adults| INTRA-CELL THRP (NASDAQ: ITCI) | Delayed: 72.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $72.00 | 52 Week High | $59.96 | |||
| Open | $72.00 | 52 Week Low | $10.80 | |||
| Day High | $72.00 | P/E | N/A | |||
| Day Low | $72.00 | EPS | $0.00 | |||
| Volume | 634 | |||||
